DB Drugs Flashcards
Clues a patient has T1DM
Young ,slender, sudden onset, DKA (ketoacidosis), undx levels of C-peptide
Tx a person in T1DM with ketoacidosis
Premeal rapid-acting insulin (aspart) with glargine at bed time
Tx a T1DM pt and in an emergent situation
give regular insulin bc only one that can be given via IV
________ can precipitate if there is a change in body temperature /pkA
insulin glargine
MOA of insulin
- binds to receptor
- P13K-AKT pathway (phosphoinositude -3 - kinase)
1. makes lipids, fats and glycogen
2. puts GLUT4 on cell surface
- P13K-AKT pathway (phosphoinositude -3 - kinase)
- MAPK pathway
1. gene transcription and cell proliferation
- MAPK pathway
Insulin is an anabolic hormone and does what
- moves GLUT 4 on membrane
- glycolysis and glycogen synthesis
- Inhibits gluconeogenesis and glycogenolysis
most imp electrolyte to watch in T1DM on insulin therapy
- K+: bc insulin moves Na/K+ATPase on membrane and moves K+ into cells
when is hyperkalemia most common
T1DM pt with DKA
what do we see in patient with DKA
- insulin def
- Acidosis
- Hyperosmolarity
Pt has T2DM and takes a drug that causes hypoglycemia. what is the most common
- Sulfonylrurea drugs and meglitinide drugs (insulin secreting drugs)
Highest risk of hypoglycemia
insulin (T1DM)
Moderate risk of hypoglycemia
- Sulfonylurea/ non-sulfonurea drugs = insulin secreting
Low risk of hypoglycemia
Glucose-dependent insulinotropism drugs = do not induce the release of insulin themselves; they enhance the release of insulin when hyperglycemic d/t ATP
- DDP-4 inhibitors
- GLP-1 AGO
Euglycemic drugs (ONLY decrease levels of glucose in HYPERGLYCEMIC pt; not in a person with NL glucose levels)
- 1. Biguanides
- 2. SGLT2-I
- 3. Alpha-glycosidase inhibitors
- 4. Thiazoladindiones
Does cause hypoglycemia when taking w other drugs
Glucose-dependent insulinotropism drugs
those that enhance ther release of insulin when pt is HYPERGLYCEMIC d/t ATP; does not release it themselves
- DDP4-I
- GLP-receptor AGO